Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
Abstract
Although most patients with newly diagnosed high-risk neuroblastoma (NB) achieve remission after initial therapy, more than 50% experience late relapses caused by minimal residual disease (MRD) and succumb to their cancer. Therapeutic strategies to target MRD may benefit these children. We developed a new chimeric antigen receptor (CAR) targeting glypican-2 (GPC2) and conducted iterative preclinical engineering of the CAR structure to maximize its anti-tumor efficacy before clinical translation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2023
- Source ID
- 10.1136/jitc-2022-005881
Entities
People
- Carol J. Thiele
- Charlie Seibert
- Fiorella Schischlik
- Haiying Qin
- Hannah G Stack
- Jeyshka M Reyes-gonzález
- Michael C. Kelly
- Ming Sun
- Mitchell Ho
- Nan Li
- Reona Okada
- Rosa Nguyen
- Yingying Cao
Organizations
- Frederick National Laboratory for Cancer Research
- National Institutes of Health
- United States Department of Defense